Loading
Life sciences · Observational Study
ClinicalTrials.gov · November 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07917364). This is a study registration, not published results. Lead sponsor: University of Applied Sciences in Nowy Targ. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 110 participants (ESTIMATED). Conditions: Metabolic Syndrome, Insulin Resistance, Obesity, Abdominal, Dyslipidemias. Interventions: DIAGNOSTIC_TEST: Biomarker panel (asprosin, microRNA, BDNF, cortisol); OTHER: Clinical and questionnaire assessment. Primary outcome measures: Serum asprosin concentration , At the single study visit (Day 1); Expression of selected circulating microRNAs , At the single study visit (Day 1). Brief summary: Metabolic syndrome is a major risk factor for cardiovascular disease and type 2 diabetes, and its prevalence in young adults is increasing. Early identification of individuals at risk may improve prevention strategies. This observational, cross-sectional case-control study investigates the relationship between serum asprosin concentration, the expression of six selected circulating microRNAs, and the components and risk factors of metabolic syndrome in young women aged 18 to 35 years. Two equally sized groups will be compared: women meeting NCEP ATP III criteria for metabolic syndrome and healthy age-matched controls. Participants attend a single study visit during which fasting blood samples, anthropometric and body composition measurements, blood pressure, and validated questionnaires assessing physical activity, diet, sleep quality, perceived stress, and quality of life are collected. The study aims to determine whether asprosin and the selected microRNA profile have diagnostic value as biomarkers of metabolic syndrome in this population.